Denosumab: mechanism of action and clinical outcomes

Abstract

AIMS: To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. METHODS: Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. FINDINGS: Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high-risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. DISCUSSION: Effective pharmacotherapy is necessary for patients at high risk of fracture. Among the treatment options for postmenopausal osteoporosis, there are significant differences in mechanism and dosing. Denosumab acts by a novel mechanism and is administered twice yearly by subcutaneous injection. Identified by Osteoporosis Canada Clinical Practice Guidelines as a first-line agent for treatment of postmenopausal osteoporosis, denosumab represents an important addition to our treatment options.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 59

1. 1.

   Rizzoli R, Yasothan U, Kirkpatrick P. Denosumab. Nat Rev Drug Discov. 2010;9:591-2.

   Not in our library10.1038/nrd3244

2. 2.

   Kanis JA, Johansson H, Oden A, McCloskey EV. Assessment of fracture risk. Eur J Radiol. 2009;71:392-7.

   Not in our library10.1016/j.ejrad.2008.04.061

3. 3.

   Hussar DA, Stevenson T. New drugs: denosumab, dienogest/estradiol valerate, and polidocanol. J Am Pharm Assoc. 2010;50:658-62.

   Not in our library10.1331/japha.2010.10536

4. 4.
   The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study · 2008

   No notice
5. 5.

   Papaioannou A, Joseph L, Ioannidis G, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2005;16:568-78.

   Not in our library10.1007/s00198-004-1735-x

6. 6.

   Perez-Lopez FR. Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas. 2007;58:117-37.

   Not in our library10.1016/j.maturitas.2007.05.002

7. 7.

   Belavic JM. Denosumab (Prolia): a new option in the treatment of osteoporosis. Nurse Pract. 2011;36:11-2.

   Not in our library10.1097/01.npr.0000391178.47878.73

8. 8.

   Brown JP, Fortier M. Canadian Consensus Conference on Osteoporosis, 2006 Update. J Obstet Gynec Canada. 2006;172:S95-112.

   Not in our library10.1016/s1701-2163(16)32087-4

9. 9.

   Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov. 2002;1:784-96.

   Not in our library10.1038/nrd916

10. 10.

    MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.

    Not in our library10.7326/0003-4819-148-3-200802050-00198

11. 11.

    Prolia Product Monograph. 2011.

    Not in our library

12. 12.

    Lipton A, Goessl C. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011;48:96-9.

    Not in our library10.1016/j.bone.2010.10.161

13. 13.

    Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972-80.

    Not in our library10.1210/jc.2010-1502

14. 14.

    Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ Canadian Medical Association Journal. 2010;182:1864-73.

    Not in our library10.1503/cmaj.100771

15. 15.

    Papaioannou A, Morin S, Cheung AM, et al.

    Not in our library

16. 16.

    Ontario’s strategy paves the way for better care across Canada. Osteoporos Update. 2005;9:6-7.

    Not in our library

17. 17.

    Leslie WD, O’Donnell S, Lagace C, et al. Population-based Canadian hip fracture rates with international comparisons. Osteoporos Int. 2010;21:1317-22.

    Not in our library10.1007/s00198-009-1080-1

18. 18.

    Adachi JD, Adami S, Gehlbach S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010;85:806-13.

    Not in our library10.4065/mcp.2010.0082

19. 19.

    Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010;95:1174-81.

    Not in our library10.1210/jc.2009-0852

20. 20.

    Hiligsmann M, Rabenda V, Bruyere O, Reginster JY. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy. 2010;96:170-7.

    Not in our library10.1016/j.healthpol.2010.01.014

21. 21.

    Bessette L, Ste-Marie LG, Jean S, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19:79-86.

    Not in our library10.1007/s00198-007-0426-9

22. 22.

    Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-9.

    Not in our library10.1016/j.bone.2008.04.007

23. 23.

    Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:S1-34.

    Not in our library

24. 24.

    Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int. 2003;14(Suppl. 3):S2-8.

    Not in our library10.1007/s00198-002-1340-9

25. 25.

    Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-37.

    Not in our library10.1210/edrv.21.2.0395

26. 26.

    Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006;116:1186-94.

    Not in our library10.1172/jci28550

27. 27.

    Rosen CJ, Bilezikian JP. Anabolic Therapy for Osteoporosis. J Clin Endocrinol Metab. 2001;86:957-64.

    Not in our library10.1210/jcem.86.3.7366

28. 28.

    Pallan S, Khan A. Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician. 2011;57:184-9.

    Not in our library

29. 29.

    Hanley DA, Watson PM, Hodsman AB, Dempster DM, Bilezikian JP, Raisz LG, Martin TJ. Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone. Principles of Bone Biology. 2008;1661-95.

    Not in our library

30. 30.

    File E, Deal C. Clinical update on teriparatide. Curr Rheumatol Rep. 2009;11:169-76.

    Not in our library10.1007/s11926-009-0023-3

31. 31.

    Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677-92.

    Not in our library10.1016/j.bone.2010.11.020

32. 32.

    Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165:1-10.

    Not in our library10.1530/eje-11-0132

33. 33.

    Cranney Ae G, Willan A, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16.

    Not in our library10.1210/er.2001-2002

34. 34.

    Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-59.

    Not in our library10.1007/s00198-007-0540-8

35. 35.

    Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97-106.

    Not in our library10.1016/s8756-3282(99)00116-7

36. 36.

    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.

    Not in our library10.1001/jama.282.7.637

37. 37.

    Apo-Raloxifene Product Monograph. 2006.

    Not in our library

38. 38.

    Yan MZ, Xu Y, Gong YX, et al. Raloxifene inhibits bone loss and improves bone strength through an OPG-independent mechanism. Endocrine. 2010;37:55-61.

    Not in our library10.1007/s12020-009-9267-y

39. 39.

    Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-26.

    Not in our library10.1016/s0140-6736(02)08827-x

40. 40.

    Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276:1389-96.

    Not in our library

Cited by papers we hold 6

• Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review · 2021
  No notice
• The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis · 2021
  No notice
• RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise‐Induced Bone Remodeling · 2020
  No notice
• Molecular Mechanisms and Emerging Therapeutics for Osteoporosis · 2020
  No notice
• Exercise and bone health across the lifespan · 2017
  No notice
• Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.